<DOC>
	<DOCNO>NCT01351480</DOCNO>
	<brief_summary>The purpose study determine use sub-cutaneous ( SC ) abatacept provide structural benefit patient rheumatoid arthritis fail prior use TNF therapy .</brief_summary>
	<brief_title>Benefits Injectable Abatacept Using Magnetic Resonance Imaging ( MRI ) Rheumatoid Arthritis ( RA ) Patients</brief_title>
	<detailed_description>Results literature suggest structural benefit intravenous ( IV ) abatacept measure high low field MRI X-ray patient rheumatoid arthritis previously fail clinical treatment TNF agent . This study attempt measure structural benefit SC abatacept similar cohort patient time compare structural finding clinical outcome measurement collect corresponding time point automate patient physician disease activity score system 28 joint ( DAS28 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Able willing give write informed consent Patients must diagnosis rheumatoid arthritis &gt; 3 month Patients must receive methotrexate 12 week prior screen dose 10mg 25 mg weekly . Patient must inadequate response receive previously receive one ( 1 ) two ( 2 ) antiTNF biologic agent Age &gt; /= 18 yr Must active RA define DAS28 ( Erythrocyte sedimentation rate ) score &gt; 4.4 Must synovitis least two joint one hand/wrist screen baseline Must negative Pregnancy test use adequate method contraception throughout trial Stable use Corticosteroids permit Stable use Nonsteroidal antiinflammatory drug permit Functional Class IV Pregnancy breastfeed History inflammatory arthritis Sexually active patient use acceptable birth control Subjects undergone metacarpophalangeal ( MCP ) arthroplasty anticipate need procedure Subjects history cancer last five year non melanoma skin cancer Subjects unable comply study followup procedure Subjects current severe symptom renal , hepatic , hematologic , gastrointestinal , pulmonary cardiac , neurologic , cerebral disease Subjects currently abuse drug alcohol Subjects evidence active latent bacterial viral infection time enrollment Subjects receive live vaccine within 4 month first dose study medication Subjects herpes zoster cytomegalovirus resolve less two month prior dose Subjects risk tuberculosis ( TB ) . Specifically excluded subject history active TB within last 3 year subject latent TB must negative chest Xray start treatment least 28 day prior dose . Prior treatment Rituximab within 12 month Prior treatment 2 TNFs Intramuscular ( IM ) , Intravenous ( IV ) Intraarticular ( IA ) corticosteroid within 28 day prior baseline Subjects metal device affect MRI ( e.g . type electronic , mechanical magnetic implant , metal sliver , metal object , cardioverter defibrillator ) Subjects received disease modify agent ( DMARD ) methotrexate within past 28 day prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Auto-immune Disease</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>